share_log

Canopy Growth | 8-K: Canopy Growth Reports Fourth Quarter and Fiscal Year 2024 Financial Results; Q4 FY2024 Net Revenue increased 7% year-over-year, or 16% excluding divested businesses

Canopy Growth | 8-K: Canopy Growth Reports Fourth Quarter and Fiscal Year 2024 Financial Results; Q4 FY2024 Net Revenue increased 7% year-over-year, or 16% excluding divested businesses

Canopy Growth | 8-K：Canopy Growth公佈第四季度和2024財年財務業績；第四季度 FY2024 淨收入同比增長7％，不包括剝離的業務，增長16％
美股sec公告 ·  05/30 19:13
牛牛AI助理已提取核心訊息
On May 30, 2024, Canopy Growth Corporation, a leading cannabis company, announced its financial results for the fourth quarter and fiscal year ended March 31, 2024. The report highlighted a 7% increase in Q4 FY2024 net revenue year-over-year, with a notable 43% increase in net revenue from Storz & Bickel, driven by strong sales of the new Venty portable vaporizer. The Canadian medical cannabis net revenue also saw a 16% increase in Q4 FY2024 and a 10% increase for the full fiscal year. The company's cost reduction actions led to a 54% decrease in Canada cannabis Cost of Goods Sold for the fiscal year compared to the previous year. Canopy Growth's balance sheet was strengthened with no material debt obligations due until March 2026. The company's CEO, David Klein, emphasized...Show More
On May 30, 2024, Canopy Growth Corporation, a leading cannabis company, announced its financial results for the fourth quarter and fiscal year ended March 31, 2024. The report highlighted a 7% increase in Q4 FY2024 net revenue year-over-year, with a notable 43% increase in net revenue from Storz & Bickel, driven by strong sales of the new Venty portable vaporizer. The Canadian medical cannabis net revenue also saw a 16% increase in Q4 FY2024 and a 10% increase for the full fiscal year. The company's cost reduction actions led to a 54% decrease in Canada cannabis Cost of Goods Sold for the fiscal year compared to the previous year. Canopy Growth's balance sheet was strengthened with no material debt obligations due until March 2026. The company's CEO, David Klein, emphasized the focus on cannabis and momentum in the industry, with growth opportunities in Germany and the United States. CFO Judy Hong highlighted the significant progress in reducing expenses, cash burn, and debt, moving the company towards positive Consolidated Adjusted EBITDA. The financial report also included details on the company's segments, with Storz & Bickel and Canada medical cannabis showing strong performance. The report concluded with statements on forward-looking expectations and strategies for growth.
2024年5月30日，領先的大麻公司Canopy Growth Corporation公佈了截至2024年3月31日的第四季度和財年的財務業績。該報告強調，受新款Venty便攜式蒸發器的強勁銷售推動，第四季度 FY2024 淨收入同比增長7％，Storz & Bickel的淨收入顯著增長了43％。加拿大醫用大麻淨收入在 FY2024 第四季度也增長了16％，整個財年增長了10％。該公司的成本削減行動使本財年加拿大大麻的商品銷售成本與去年同期相比下降了54％。Canopy Growth的資產負債表得到加強，2026年3月之前沒有實質性債務到期。該公司首席執行官戴維·克萊因強調了對大麻的關注和該行...展開全部
2024年5月30日，領先的大麻公司Canopy Growth Corporation公佈了截至2024年3月31日的第四季度和財年的財務業績。該報告強調，受新款Venty便攜式蒸發器的強勁銷售推動，第四季度 FY2024 淨收入同比增長7％，Storz & Bickel的淨收入顯著增長了43％。加拿大醫用大麻淨收入在 FY2024 第四季度也增長了16％，整個財年增長了10％。該公司的成本削減行動使本財年加拿大大麻的商品銷售成本與去年同期相比下降了54％。Canopy Growth的資產負債表得到加強，2026年3月之前沒有實質性債務到期。該公司首席執行官戴維·克萊因強調了對大麻的關注和該行業的勢頭，德國和美國也有增長機會。首席財務官朱迪·洪強調了在減少開支、現金消耗和債務方面取得的重大進展，這使公司實現了正的合併調整後息稅折舊攤銷前利潤。財務報告還包括公司細分市場的詳細信息，Storz & Bickel和加拿大醫用大麻表現強勁。報告最後發表了關於前瞻性預期和增長戰略的陳述。

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。